#tdxd
LightNews LightNews
jameabraham.bsky.social
Expanded indication for TDXd!
ascopost.bsky.social The ASCO Post @ascopost.bsky.social · Jan 28
The FDA has approved trastuzumab deruxtecan (T-DXd) for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer based on DESTINY-Breast06 trial results. #BreastCancer #Oncology ascopost.com/news/january...
January 31, 2025 at 11:03 AM
amunicipalfox.bsky.social
youtube.com/watch?v=TDXD...
Somebody To Love
YouTube video by Basstrologe - Topic
music.youtube.com
March 17, 2025 at 12:25 AM
oncodaily.bsky.social
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer
@drsarahsammons.bsky.social @erikahamilton9.bsky.social

oncodaily.com/blog/tdxd-29...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #TDXd #HER2 #BreastCancer
Sarah Sammons Comments on TDXd Use in Early HER2+ Breast Cancer - OncoDaily
Sarah Sammons shares perspective on neoadjuvant TDXd use in HER2-positive breast cancer.
oncodaily.com
May 9, 2025 at 5:20 PM
evandahm.bsky.social
some explanatory multimedia material from the launch www.youtube.com/watch?v=tdXD...
3rd Voice Launch Video / A GRAPHIC NOVEL
YouTube video by Evan Dahm
www.youtube.com
May 11, 2026 at 10:52 PM
erikahamilton9.bsky.social
Another positive trial in #bcsm, TDXd followed by THP beats ddAC-THP in neoadjuvant HER-2+ early breast cancer.

We've seen a lot of positive TDXd results, but this is the FIRST 🥇in the early stage setting!

@oncbrothers.bsky.social
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...
Enhertu followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in patients with high-risk HER2-positive early-stage breas...
www.astrazeneca.com
May 7, 2025 at 1:01 PM
oncbrothers.bsky.social
#SABCS24 Day 1 Highlights #CommunityOnc:

1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib

2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L

3. #DB06: HR+ TDXd

4. #KN522: biomarker analysis

#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social

1/5
December 11, 2024 at 2:26 AM
evandahm.bsky.social
here's my "PITCH," from about 2 years ago www.youtube.com/watch?v=tdXD...
3rd Voice Launch Video / A GRAPHIC NOVEL
YouTube video by Evan Dahm
www.youtube.com
October 17, 2024 at 8:53 PM
evandahm.bsky.social
i am also loosely working on a new video for 2year anniversary of the launch of the thing. continuing this - www.youtube.com/watch?v=tdXD... . but no real promises on that front yet
October 26, 2024 at 5:01 PM
erikahamilton9.bsky.social
Story short, TDXd was better in all groups.

Quick or slow relapsers on DB-06

Regardless of disease burden

Among primary or secondary endocrine resistance

#SABCS24
@SABCSSanAntonio
@OncoAlert
December 11, 2024 at 12:35 AM
maraevantree.bsky.social
𝒄𝒐𝒎𝒆 𝒋𝒐𝒊𝒏 𝒚𝒐𝒖𝒓 𝒔𝒎𝒆𝒍𝒍𝒚 𝒅𝒆𝒎𝒐𝒏 𝒑𝒓𝒊𝒏𝒄𝒆𝒔𝒔 𝒂𝒇𝒕𝒆𝒓 𝒂 𝒒𝒖𝒊𝒄𝒌 𝒔𝒉𝒐𝒘𝒆𝒓!🚿🫧₊ ⊹
www.youtube.com/watch?v=tDxd...
July 17, 2026 at 6:55 PM
erikahamilton9.bsky.social
DB-06 #TDXD approved for HER-2 "ultra low" (IHC but staining) breast cancer, and 1st line moving this drug up.

#bcsm
@oncoalert.bsky.social

www.astrazeneca.com/media-centre...
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
www.astrazeneca.com
January 27, 2025 at 11:19 PM
futagawakasara.bsky.social
www.youtube.com/watch?v=TDxd...
クリスマスに家にやってくるカスのおねえちゃん
YouTube video by Utsuro CH. 氷室うつろ
www.youtube.com
December 27, 2025 at 12:36 PM
stage4kelly.bsky.social
Also for ER+ (b/c I’m still ER+) is DB06, where there was efficacy even in HER2 ultra low (seriously, where is TDXd (Enhertu) NOT effective - it crosses the BBB too! #SABCS24
December 13, 2024 at 11:44 PM
stage4kelly.bsky.social
And while PFS with TDXd was better, there were 3 deaths due to ILD. #SABCS24
December 11, 2024 at 11:06 PM
maraevantree.bsky.social
𝑰𝑴 𝑯𝑬𝑹𝑬 𝑨𝑵𝑫 𝑰 𝑺𝑻𝑨𝑹𝑻𝑬𝑫 𝑴𝒀 𝑷𝑬𝑹𝑰𝑶𝑫!
www.youtube.com/watch?v=tDxd...
July 17, 2026 at 8:04 PM
jameabraham.bsky.social
DESTINY 05 trial - in high risk her - 2 positive #breastcancer - 53% reduction in invasive disease free survival with TDXd - @NSABPFoundation @myesmo.bsky.social @oncoalert.bsky.social ! Honored to be part of the study ! @clevelandclinic.bsky.social
October 18, 2025 at 11:07 PM
marthacarlson.bsky.social
What are clinicians going to do about lines after TDXd in metastatic breast cancer? I hope it gets better than this ⬇️ for the sake of myself and so many people I know
www.thebreastonline.com/action/showP...
www.thebreastonline.com
September 30, 2026 at 1:17 PM
lizzysmyth.bsky.social
Good to see our protocol paper for DECIPHER in press at ESMO GO!

ctDNA 🧬 after surgery will detect pts with HER2➕ gastroesophageal #cancer at high risk of recurring

🧬➕ receive TDxD instead of usual post-op chemo

Hope to #cure some micrometastatic cancers 🙏

www.sciencedirect.com/science/arti...
Evaluating trastuzumab deruxtecan in patients with gastrooesophageal adenocarcinoma who are ctDNA and HER2 positive: DECIPHER
Operable gastrooesophageal adenocarcinoma (GOA) is treated with multimodality therapy which is curative in <50% of patients. Patients in the UK with o…
www.sciencedirect.com
December 1, 2024 at 11:18 AM
oncodaily.bsky.social
Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - Olubukola Ayodele
@bookiephronesis.bsky.social

oncodaily.com/blog/olubuko...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Lisbon #BreastCancer #TDXd
Olubukola Ayodele: Discussing T-DXd toxicities in breast cancer at a thought-provoking meeting in Lisbon - OncoDaily
Olubukola Ayodele shares insights from a Lisbon meeting on managing T-DXd toxicities in metastatic HER2-positive breast cancer.
oncodaily.com
April 30, 2025 at 2:35 PM
drgattimays.bsky.social
Happy to share our retrospective study on #pneumonitis risk in patients with #breastcancer who receive #TDXd #Enhertu @stoverlab.bsky.social @osucccjames.bsky.social #bcsm
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer - Breast Cancer Research
Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment...
breast-cancer-research.biomedcentral.com
February 3, 2025 at 11:18 PM
father.vol.army
TDxD
March 12, 2024 at 1:29 PM
tnewsomdavis.bsky.social
And we’re off!

Meenali Chitnis opens the therapeutic symposium with targeting HER2: ADCs or TKI?

TKIs win in for me

Especially given that TDxd not available in 🇬🇧 for lung cane, given that NICE application has been withdrawn

#BTOG25
March 3, 2025 at 11:16 AM
getpaulhoward.bsky.social
You might have heard...
I'm at Institute on Violence, Abuse and Trauma's International Summit and I'll be going LIVE again today, 1:15pm (PST) to share some of the exhibitors involved... tune in!! @ivatjournals.bsky.social

www.youtube.com/watch?v=TdXD...
Meet the Exhibitors — LIVE from IVAT Day 1
YouTube video by Paul Howard
www.youtube.com
September 24, 2026 at 7:21 PM
danafarbernews.bsky.social
Now at #ASCO25, @danafarber.bsky.social’s Sara Tolaney, MD, shares results of DESTINY-09: TdxD + pertuzumab nearly doubled PFS in pts with newly dx HER2+ mbc. Findings could be new standard of care for these pts for the first time in a decade.

➡️ bit.ly/4dEUVYj
Sara Tolaney, MD, of Dana-Farber Cancer Institute
June 2, 2025 at 12:00 PM
onco404.bsky.social
Primary results from a phase 2a study show #Zanidatamab + #Palbociclib + #Fulvestrant is a promising chemotherapy-free option for heavily pretreated HR+/HER2+ MBC patients.

@thelancetoncol.bsky.social

#Onco404 #Cancer #Kanser #BreastCancer #ClinicalTrials #HER2 #ADC #TDXd #Healthcare #Innovation
May 9, 2025 at 5:59 PM